Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1930 - Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cut-off Value


09 Sep 2017


Poster display session


Yusuke Yamamoto


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


Y. Yamamoto1, T. Sugiura2, Y. Okamura2, T. Ito2, R. Ashida2, K. Uesaka2

Author affiliations

  • 1 Division Of Hepato-biliary-pancreatic Surgery, Shizuoka Cancer Center, 4118777 - Shizuoka/JP
  • 2 Division Of Hepato-biliary-pancreatic Surgery, Shizuoka Cancer Center, Shizuoka/JP


Abstract 1930


The EASL guidelines for intrahepatic cholangiocarcinoma (ICC) discouraged resection for ICC patients with lymph node metastasis (LNM), intrahepatic metastasis (IM), or vascular invasion (VI). The clinical impact of hepatectomy in ICC patients with IM, periductal infiltration (MF+PI), LNM, and VI remains unclear.


Patients ICC who underwent hepatectomy for MF dominant ICC and unresected patients due to IM, LNM, or locally advanced tumors (unresectable group) were enrolled. The clinical impact of CA19-9 and hepatectomy were evaluated in ICC. The best CA19-9 cut-off value for ICC was examined based on the overall survival (OS). The surgical outcomes of patients who underwent hepatectomy for ICC with LNM, IM, VI, or PI were investigated, and survival of those patients was compared with that of patients with unresectable ICC based on their prognostic factors.


A total of 73 resected patients and 20 unresectable patients were enrolled. The optimal CA19-9 cut-off value (based on the greatest difference in overall survival [OS]), was 300 U/mL. The OS at CA19-9


Even if ICC patients develop IM, PI, LNM, or VI, or require major vascular resection, hepatectomy can be considered for selected patients with CA19-9

Clinical trial identification

Legal entity responsible for the study

Yusuke Yamamoto




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.